Researchers determine a complex immune infiltrate pattern based on a newly constructed immune map developed using pancreatic cancer cells.

Explore how T cell engagers could transform cancer and autoimmune treatments through promising trials and key collaborations.

PLC ("TC BioPharm" or the "Company")  a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced the first ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

HURA READ THE FULL HURA RESEARCH REPORT We are initiating coverage of TuHURA Biosciences, Inc. (NASDAQ:HURA) with a valuation of $9.25 per share. This value is based on our estimates for successful ...

Inc. (Nasdaq: TSVT) today provided full-year Abecma® (idecabtagene vicleucel; ide-cel) sales results for 2024, in partnership with Brist ...

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Annual Symposium held in San ...

Plasma samples from P. vivax-infected patients (PV ... Human SCSs were processed to separate T lymphocytes, myeloid cells and RBCs. First, cell suspensions were diluted up to 5 × 10 7 cells/mL with ...

Additionally, their impact on the myeloid cells renders them capable of addressing ... These approahes effectively eliminate B cells and/or plasma cells through signaling disruption, ...

SLPI reprogrammes myeloid cells towards resolution responses by inducing the prorestorative ... of acetaminophen and metabolites in mouse plasma Mouse plasma samples were analysed for acetaminophen ...

Background Treatment strategies for Crohn’s disease (CD) suppress diverse inflammatory pathways but many patients remain ...

Treatment with a cold atmospheric plasma reduced the recurrence rate of melanoma tumours after surgery by roughly 50% ...